Thomas Eugene White
Physician at Skyline Blvd, Oakland, CA
License number
Colorado 29686
Issued Date
Jul 13, 1989
Renew Date
Jun 1, 2009
Expiration Date
May 31, 2011
Type
Physician
Address
Address
7875 Skyline Blvd, Oakland, CA 94611
Personal information
See more information about Thomas Eugene White at radaris.comName
Address
Phone
23515 Lyons Ave UNIT 210, Valencia, CA 91355
5112 Dawes St, San Diego, CA 92109
520 Sand Hill Rd, Palo Alto, CA 94304
522 Carla Ave, Chula Vista, CA 91910
517 Fernwood Dr, Moraga, CA 94556
Professional information
See more information about Thomas Eugene White at trustoria.com
Human Il-2 As A Vaccine Adjuvant
Human Il-2 As A Vaccine Adjuvant
US Patent:
6060068, May 9, 2000
Filed:
Aug 31, 1998
Appl. No.:
9/144581
Inventors:
Michael V. Doyle - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 3820, A61K 3902, A61K 3912
US Classification:
4242781
Abstract:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
Method For Diagnosis Of Lyme Disease
Method For Diagnosis Of Lyme Disease
US Patent:
5912117, Jun 15, 1999
Filed:
Oct 9, 1992
Appl. No.:
7/923871
Inventors:
Deborah E. Dodge - Albany CA
Thomas J. White - Oakland CA
Thomas J. White - Oakland CA
Assignee:
Roche Molecular Systems, Inc. - Branchburg NJ
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
Methods and reagents are provided for amplifying and detecting target nucleic acid sequences in a sample suspected of containing Borrelia spirochetes using the polymerase chain reaction (PCR) process. The PCR process employs primers and probes which are derived from the 16S ribosomal RNA gene of Borrelia burgdorferi and Borrelia hermsii.
Human Il-2 As A Vaccine Adjuvant
Human Il-2 As A Vaccine Adjuvant
US Patent:
5643565, Jul 1, 1997
Filed:
May 24, 1995
Appl. No.:
8/448884
Inventors:
Michael V. Doyle - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 3820
US Classification:
424 852
Abstract:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
Human Il-2 As A Vaccine Adjuvant
Human Il-2 As A Vaccine Adjuvant
US Patent:
5800810, Sep 1, 1998
Filed:
Oct 17, 1996
Appl. No.:
8/734471
Inventors:
Michael V. Doyle - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 3820
US Classification:
424 852
Abstract:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
Method Of Controlling Stress-Related Disease In Livestock By Administration Of Human Il-2
Method Of Controlling Stress-Related Disease In Livestock By Administration Of Human Il-2
US Patent:
4818769, Apr 4, 1989
Filed:
Apr 25, 1986
Appl. No.:
6/856680
Inventors:
Jack H. Nunberg - Oakland CA
Michael Doyle - Oakland CA
Arthur Newell - Orinda CA
Thomas White - Oakland CA
Michael Doyle - Oakland CA
Arthur Newell - Orinda CA
Thomas White - Oakland CA
Assignee:
Cetus Corporation - Emeryville CA
International Classification:
A61K 3702
US Classification:
514 2
Abstract:
Disclosed herein is a method of mitigating stress-related syndromes in livestock, such as shipping fever in cattle, by administration of human IL-2.
Human Il-2 As A Vaccine Adjuvant
Human Il-2 As A Vaccine Adjuvant
US Patent:
5100664, Mar 31, 1992
Filed:
Jun 30, 1989
Appl. No.:
7/374602
Inventors:
Michael V. Doyle - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Gary A. Anderson - Bucyrus KS
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Gary A. Anderson - Bucyrus KS
Assignee:
Cetus Corporation - Emeryville CA
International Classification:
A61K 3702, A61K 4502, A61K 4505
US Classification:
424 92
Abstract:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
Human Il-2 As A Vaccine Adjuvant
Human Il-2 As A Vaccine Adjuvant
US Patent:
5503841, Apr 2, 1996
Filed:
Feb 24, 1989
Appl. No.:
7/314975
Inventors:
Michael V. Doyle - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Arthur D. Newell - Orinda CA
Jack H. Nunberg - Oakland CA
Thomas J. White - Oakland CA
Assignee:
Cetus Oncology Corporation - Emeryville CA
International Classification:
A61K 3820, A61K 3902, A61K 3912
US Classification:
4242781
Abstract:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.